Codex Therapeutics

Codex Therapeutics is developing a topical gel from human HSP90 alpha protein to substantially reverse chronic wound healing times.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Parsippany-Troy Hills, NJ, USA
  • Currency USD
  • Founded April 2012
  • Employees 3

Company Summary

Codex is currently focusing on the preclinical development of its leading drug candidate, CT-115, which has already shown potent efficacy in the FDA's assessment criteria of 100% Wound Healing Incidence and near normal Healing Time in mice and pigs. The drug is targeted to treat diabetic, pressure, and venous ulcers where there remains significant unmet clinical need and for which the NIH estimates rising annual care costs of >$25B annually.

Team

  • Jean A. Berthold
    CEO

    Experienced Entrepreneur with award-winning business plans, sales & marketing growth strategies, & new technology deployment success. Broad C-Suite contribution as Chief Marketing & Sales, Operations & Executive Officer roles and Board Director service with Delaware C Corp fiduciary responsibility, corporate governance, legal & HR, equity fund raising, and M&A Experience in Biomedical Instrumentation, Pharmaceutical Research, Process & Quality Co

  • Wenshan Hao, Ph.D.
    CTO

    Creative serial biotech entrepreneur. Passionate for developing disruptive technologies and treatments that address significantly unmet clinical needs in multiple disease areas. Co-founder of Codex Therapeutics Inc. In 2010 Wenshan invested to start up U-Pharm Laboratories LLC at Parsippany, NJ, to conduct pharmacological drug discovery services for pharmaceutical and biotech industry and incubate and develop innovative/leading early-stage drug d

  • Wenshan Hao

Advisors

  • Jonathan W. Emery, Esq. from Bressler, Amery & Ross, P.C.
    Lawyer
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free